Adhera Therapeutics, Inc.
ATRX
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.95% | -16.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.95% | -16.15% | |||
| Operating Income | 8.95% | 16.15% | |||
| Income Before Tax | -1,404.72% | 130.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,404.72% | 130.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,404.72% | 130.59% | |||
| EBIT | 8.95% | 16.15% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -1,269.21% | 124.66% | |||
| Normalized Basic EPS | -1,315.33% | 123.30% | |||
| EPS Diluted | -5,704.20% | 95.02% | |||
| Normalized Diluted EPS | -34,453.33% | 100.82% | |||
| Average Basic Shares Outstanding | 24.30% | 8.99% | |||
| Average Diluted Shares Outstanding | -95.63% | 3,001.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||